19:54 , Jan 13, 2017 |  BC Week In Review  |  Company News

InVivo, PixarBio deal

PixarBio proposed to acquire InVivo for $100 million in stock. The combined company would be renamed Reynolds Therapeutics Corp. and focus on pain, spinal cord injury, adaptive technologies, epilepsy and Parkinson's disease. According to PixarBio,...
07:00 , Jul 14, 2014 |  BioCentury  |  Finance

2Q Stock Wrap-Up: Large and in charge

In contrast to the first quarter in which all market cap segments gained ground, only the large caps finished 2Q14 in the black. Gainers outnumbered decliners 20-12 in the over $5 billion segment, which was...
07:00 , Jun 30, 2014 |  BC Week In Review  |  Company News

InVivo Therapeutics neurology news

InVivo will reduce headcount by 14 (28%) to 36 and will discontinue development of its hydrogel drug delivery program, which was in an “early stage” of preclinical development. The company said the move will save...
07:00 , Apr 8, 2013 |  BC Week In Review  |  Clinical News

Biopolymer scaffolding regulatory update

FDA granted Humanitarian Use Device designation for its biopolymer scaffolding to treat recent complete spinal cord injury that does not involve penetrating injury or the complete severing of the spinal cord. InVivo said it expects...
08:00 , Dec 24, 2012 |  BC Week In Review  |  Clinical News

Biopolymer scaffolding regulatory update

InVivo said it submitted a request to FDA seeking Humanitarian Use Device (HUD) designation for its biopolymer scaffolding to treat complete functional spinal cord injuries that do not involve penetrating injury or the complete severing...